Metabolic Testing Market to Reach USD 972.26 Million by 2029 as Demand for Personalized Health Assessment Accelerates

Metabolic Testing Market Overview

The Metabolic Testing Market is expanding as healthcare providers, sports organizations, laboratories, and wellness centers increasingly adopt technologies capable of measuring metabolic performance and energy expenditure. According to Maximize Market Research, the global market was valued at USD 589.48 million in 2022 and is expected to reach approximately USD 972.26 million by 2029, growing at a CAGR of 7.41% from 2023 to 2029.

Metabolic testing provides objective information about oxygen consumption, resting metabolic rate, body composition, and energy expenditure, supporting more personalized healthcare and performance-management strategies. The growing prevalence of lifestyle-associated conditions, including obesity, cardiovascular diseases, and diabetes, is a major factor increasing demand for metabolic assessments. Rising healthcare expenditure, technological advancements, greater health awareness, and improving living standards are also supporting market expansion.

The increasing adoption of metabolic testing in hospitals and critical-care environments represents a significant opportunity. Metabolic testing equipment and software can help healthcare professionals assess energy requirements and support nutrition management. In sports medicine, these systems are increasingly used to measure aerobic capacity, optimize exercise programs, and develop individualized training strategies.

The market is also benefiting from the growing popularity of preventive healthcare and personalized weight-management programs. Metabolic measurements can provide information that helps healthcare professionals develop individualized nutrition and exercise plans instead of relying solely on generalized calculations.

Technological innovation is further creating opportunities. Portable metabolic monitors, simplified workflows, improved gas-analysis sensors, integrated software, and digitally connected systems are making metabolic testing more accessible across clinical and performance environments. COSMED, for example, offers portable Q-NRG systems for indirect calorimetry, while its Q-NRG+ platform supports both spontaneously breathing and mechanically ventilated patients.

Nevertheless, high equipment and software costs and limited reimbursement remain constraints. Expanding access in developing economies represents a significant opportunity for manufacturers as healthcare spending and awareness increase.

* Get Strategic Business Intelligence: https://www.maximizemarketresearch.com/request-sample/21402/ 

U.S. Market Trends and Investment

The United States was a significant market in 2022, supported by technological advancement in metabolic testing and the high prevalence of lifestyle-related diseases. The U.S. market is also benefiting from the wider shift toward personalized nutrition, preventive healthcare, sports performance assessment, and technology-enabled clinical care.

In 2025, companies operating across healthcare diagnostics continued investing in advanced testing technologies and U.S. manufacturing. Abbott announced USD 500 million of investments in U.S. manufacturing and R&D, with projects in Illinois and Texas expected to become operational by the end of 2025. Although the investment spans Abbott's broader diagnostics and healthcare portfolio rather than metabolic testing alone, it demonstrates continued industry commitment to advanced diagnostic infrastructure.

Metabolic testing technology itself is also becoming more portable and user-friendly. COSMED's Q-NRG platform provides point-of-care indirect calorimetry, while its Q-NRG+ system is designed for clinical and critical-care applications. These developments can expand adoption by reducing workflow complexity and enabling metabolic measurements in more clinical settings.

Market Segmentation

According to the MMR report, the Metabolic Testing Market is segmented by Product, Technology, Application, End User, and Region.

By product, the market includes CPET Systems, Metabolic Carts, Body Composition Analyzers, ECGs & EKGs Attachable to CPET Systems, and Software.

By technology, the segments are VO2 Max Analysis, RMR Analysis, and Body Composition Analysis. The VO2 Max Analysis segment is expected to hold a significant share, supported by its broad use among athletes, healthy individuals, and patients. VO2 max testing measures oxygen consumption and provides an objective indicator of aerobic capacity.

By application, the market includes Lifestyle Diseases, Critical Care, Human Performance Testing, Dysmetabolic Syndrome X, Metabolic Disorders, and Other Applications. The Lifestyle Diseases segment is expected to witness significant growth because of the rising prevalence of obesity, diabetes, and cardiovascular diseases.

By end user, the market includes Hospitals, Laboratories, Sports Training Centers, Gyms, and Other End Users.

Metabolic Testing Market Key Players are:
1.OSI Systems Inc.
2.Carefusion Corporation
3.General Electric Company
4.AEI Technologies Inc.
5.MGC Diagnostics Corporation
6.Geratherm Medical AG
7.Parvo Medics
8.Microlife Medical Home Solutions Inc.
9.Cosmed
10.Korr Medical Technologies Inc.
11.Cortex Biophysik Gmbh.
12.AEI Technologies, Inc.
13.OSI Systems, Inc.
14.Cortex Biophysik GmbH
15.Medical Home Solutions, Inc.
16.MGC Diagnostic Corporation
17.VacuMed
18.Merck KGaA
19.Abbott
20.Admera Health
21.Endurance Company, LLC,
22.PreventiNe Life Care
23.Promega Corporation
24.CareFusion Corporation

Competitive Analysis

The MMR report identifies OSI Systems Inc., CareFusion Corporation, General Electric Company, AEI Technologies Inc., MGC Diagnostics Corporation, Geratherm Medical AG, Parvo Medics, Microlife Medical Home Solutions Inc., COSMED, Korr Medical Technologies Inc., Cortex Biophysik GmbH, VacuMed, Merck KGaA, Abbott, Admera Health, Endurance Company LLC, PreventiNe Life Care, and Promega Corporation, among other companies, as key participants.

The report does not provide individual percentage market shares for the five leading companies, so exact shares have not been fabricated.

General Electric Company remains an important healthcare technology participant. GE HealthCare reported USD 20.6 billion in 2025 revenue, with capital expenditure of USD 482 million, compared with USD 401 million in 2024, while stating that it continued to prioritize investment in innovation and capacity expansion.

COSMED is focused directly on metabolic and cardiopulmonary testing. Its Q-NRG systems provide indirect calorimetry for clinical and critical-care applications, while the Q-NRG Max supports VO2 max and resting-energy-expenditure assessment. In September 2025, COSMED completed the acquisition of French bio-impedance specialist Bioparhom, strengthening its portfolio in body-composition and metabolic assessment.

Parvo Medics continues to offer TrueOne metabolic measurement systems for cardiopulmonary stress testing, indirect calorimetry, and maximal oxygen-consumption measurement. Its TrueOne 2400 integrates metabolic analysis hardware and software into a compact system.

MGC Diagnostics Corporation is identified by MMR as a key market participant, contributing to cardiopulmonary and metabolic diagnostic technologies for clinical and performance applications.

Abbott maintains a substantial diagnostics and healthcare technology portfolio. Its 2025 strategy included continued U.S. manufacturing and R&D investment, while the company's broader diagnostics business continues to emphasize faster, accurate testing and technology-enabled healthcare.

Regional Analysis

North America held significant growth in 2022, according to MMR, supported by technological advancement and the increasing prevalence of obesity, diabetes, and cardiovascular diseases.

The Asia Pacific region is projected to become a leading market. Rising healthcare spending, increasing demand for quality medical care, improving living standards, government initiatives, greater patient awareness, and an aging population are expected to support expansion.

Japan and China offer considerable opportunities as healthcare infrastructure develops and demand for advanced diagnostic technologies increases. Growing awareness of metabolic disorders and preventive healthcare can further accelerate adoption.

In Germany, France, and the United Kingdom, demand is supported by established healthcare systems, clinical research capabilities, and increasing interest in personalized healthcare and performance assessment.

Conclusion

The Global Metabolic Testing Market is projected to grow from USD 589.48 million in 2022 to USD 972.26 million by 2029, advancing at a 7.41% CAGR during 2023–2029.

In our view, the most significant growth opportunities will emerge from personalized nutrition, obesity and diabetes management, critical-care nutrition, sports performance testing, portable metabolic monitors, body-composition assessment, and software-integrated diagnostic systems.

The industry's future will increasingly depend on making metabolic testing more accurate, portable, affordable, and easier to operate. As healthcare moves toward personalized treatment and preventive care, technologies capable of providing objective metabolic data can become increasingly valuable across hospitals, laboratories, sports centers, and wellness facilities.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? [email protected]